COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022
Description
CONCLUSIONS AND RELEVANCE: COVID-19 rebound occurred both after Paxlovid and Molnupiravir, especially in patients with underlying medical conditions. This indicates that COVID-19 rebound is not unique to Paxlovid and the risks were similar for
